Abstract
Cancer cells are known to express cell surface molecules such as specific antigens or cytokine receptors, e.g., EGFR, Fas / CD95, gp100, HER-2 / neu, IL-13Rα2, and MAGE. Among them, interleukin-13 receptor (IL-13R) a2 chain is expressed on certain types of cancer cells including glioblastoma, AIDS Kaposis sarcoma, and head and neck cancer. This protein is one of the receptor components for IL-13, a Th2 cell-derived pleiotropic immune regulatory cytokine. IL- 13Rα2 chain on these cancer cells can be targeted with a receptor-directed cytotoxin termed IL13-PE to induce specific cancer cell killing, however, this molecule does not mediate cytotoxicity to cells that do not express or express low levels of IL-13Rα2. In order to achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene transfer of IL-13Rα2 in cancer cells was employed in vitro and in vivo. Cancer cells transfected with IL-13Rα2 demonstrated increased binding to IL-13 and sensitivity to IL13-PE in vitro. In vivo intratumoral gene transfer of IL-13Rα2 profoundly enhanced the antitumor activity of IL13-PE, providing complete elimination of established tumor in some xenografts. In this review article, current findings from IL-13Rα2 gene transfer in a variety of human cancer models in nude mice are summarized. In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed.
Keywords: cancer gene therapy, interleukin-13, cytokine receptor, immunotherapy, tumor vaccine, immunotoxin
Current Gene Therapy
Title: Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Volume: 5 Issue: 2
Author(s): Koji Kawakami
Affiliation:
Keywords: cancer gene therapy, interleukin-13, cytokine receptor, immunotherapy, tumor vaccine, immunotoxin
Abstract: Cancer cells are known to express cell surface molecules such as specific antigens or cytokine receptors, e.g., EGFR, Fas / CD95, gp100, HER-2 / neu, IL-13Rα2, and MAGE. Among them, interleukin-13 receptor (IL-13R) a2 chain is expressed on certain types of cancer cells including glioblastoma, AIDS Kaposis sarcoma, and head and neck cancer. This protein is one of the receptor components for IL-13, a Th2 cell-derived pleiotropic immune regulatory cytokine. IL- 13Rα2 chain on these cancer cells can be targeted with a receptor-directed cytotoxin termed IL13-PE to induce specific cancer cell killing, however, this molecule does not mediate cytotoxicity to cells that do not express or express low levels of IL-13Rα2. In order to achieve a broad therapeutic window for IL13-PE, plasmid-mediated gene transfer of IL-13Rα2 in cancer cells was employed in vitro and in vivo. Cancer cells transfected with IL-13Rα2 demonstrated increased binding to IL-13 and sensitivity to IL13-PE in vitro. In vivo intratumoral gene transfer of IL-13Rα2 profoundly enhanced the antitumor activity of IL13-PE, providing complete elimination of established tumor in some xenografts. In this review article, current findings from IL-13Rα2 gene transfer in a variety of human cancer models in nude mice are summarized. In addition, safety issues and possible future directions utilizing this therapeutic approach are discussed.
Export Options
About this article
Cite this article as:
Kawakami Koji, Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain, Current Gene Therapy 2005; 5 (2) . https://dx.doi.org/10.2174/1566523053544227
DOI https://dx.doi.org/10.2174/1566523053544227 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Targeting HOTAIR induces mitochondria related apoptosis and inhibits tumor growth in head and neck squamous cell carcinoma in vitro and in vivo.
Current Molecular Medicine Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Sphingolipid Modulation: A Strategy for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations
Medicinal Chemistry Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Targeting Plasmodium Falciparum Purine Salvage Enzymes: A Look At Structure-Based Drug Development
Infectious Disorders - Drug Targets Anti-Tumor Vaccines in Head and Neck Cancer: Targeting Immune Responses to the Tumor
Current Cancer Drug Targets Epigenetics and Periodontal Disease: Hope to Tame the Untameable
Current Gene Therapy Alpha-Interferon and Its Effects on Signalling Pathways Within Cells
Current Protein & Peptide Science Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety